Retatrutide continues to be investigational as of 2026. It is not FDA-authorized and cannot be prescribed or compounded outside of clinical trial participation. Those with major obesity-associated overall health ailments may perhaps moderately choose that immediate intervention justifies research chemical hazards. Other folks want looking ahead